GLP-1: benefits beyond pancreas
- 9 August 2014
- journal article
- review article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 37 (12) , 1143-1153
Abstract
Glucagon-like peptide 1 (GLP-1) is an intestinal hormone secreted after the ingestion of various nutrients. The main role of GLP-1 is to stimulate insulin secretion in a glucose-dependent manner. However, the expression of GLP-1 receptor was found to be expressed in a variety of tissues beyond pancreas such as lung, stomach, intestine, kidney, heart and brain. Beyond pancreas, a beneficial effect of GLP-1 on body weight reduction has been shown, suggesting its role for the treatment of obesity. In addition, GLP-1 has been demonstrated to reduce cardiovascular risk factors and to have a direct cardioprotective effect, fostering heart recovery after ischemic injury. Further, data from both experimental animal models and human studies have shown beneficial effect of GLP-1 on bone metabolism, either directly or indirectly on bone cells.Keywords
This publication has 122 references indexed in Scilit:
- Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protectionCardiovascular Diabetology, 2013
- Alterations in energy balance following exenatide administrationApplied Physiology, Nutrition, and Metabolism, 2012
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-AnalysisExperimental Diabetes Research, 2012
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Provides Neuroprotection in Mice Transient Focal Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 2011
- Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical resultsBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and ParkinsonismProceedings of the National Academy of Sciences, 2009
- Modulation of taste sensitivity by GLP‐1 signalingJournal of Neurochemistry, 2008
- Effects of glucagon‐like peptide‐1 and sympathetic stimulation on gastric accommodation in humans1Neurogastroenterology & Motility, 2007